This patent extends through the year 2022. Tobramycin inhalation powder (TIP) is being co-developed by Nektar and Novartis and is currently in Phase III development for the prevention and treatment of Pseudomonas aeruginosa pneumonia.
Howard Robin, Nektar’s president and CEO, said: “Issuance of this patent further demonstrates the power of Nektar’s pulmonary technology platform, as well as our industry leadership in the emerging field of targeted anti-infective therapeutics. Nektar will continue to aggressively file patents to ensure that the company remains at the forefront of our fields.”